Citadel Advisors
NVCT icon

Citadel Advisors’s Nuvectis Pharma NVCT Stock Holding History

Citadel Advisors’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,500
Closed -$109K – 13828
2025
Q4 		$109K Buy
+14,500
New +$94.5K ﹤0.01% 11559
2025
Q2 		– Sell
-11,200
Closed -$109K – 14266
2025
Q1 		$109K Buy
+11,200
New +$80.7K ﹤0.01% 11333

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's NVCT Position: Q1 2026 in Review

Citadel Advisors opened a new position in Nuvectis Pharma (NVCT) in Q1 2026: 78,425 shares worth $606K. The stake represents ﹤0.01% of the portfolio and ranks #8828 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in NVCT as recently as Q1 2025.

Citadel Advisors first reported a position in NVCT in Q2 2022 and has held it in 5 quarters since. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Citadel Advisors held 78,425 shares of Nuvectis Pharma worth $606K as of Q1 2026.
  • Nuvectis Pharma was a new Citadel Advisors position in Q1 2026.
  • Nuvectis Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8828 holding.
  • Citadel Advisors first reported a position in Nuvectis Pharma in Q2 2022 and has held it in 5 quarters since.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.